November 18, 2026

To Whom It May Concern:

Company Name: Daito Pharmaceutical Co., Ltd.
Representative: Hiroshi Matsumori, President and CEO
(Securities Code: 4577, Prime Market of Tokyo Stock Exchange)
Inquiries: Kenji Otsuga, Director, Executive Officer and CFO
(Telephone Number: +81-76-421-5665)

Notice Regarding Corrections to the English Translation of the Summary of Consolidated Financial Results for the Fiscal Year Ended May 31, 2026 (Under Japanese GAAP)

Daito Pharmaceutical Co., Ltd. (the "Company") hereby announces that it has made the following corrections to the English translation of the "Summary of Consolidated Financial Results for the Fiscal Year Ended May 31, 2026 (Under Japanese GAAP)," released on July 10, 2026. The Japanese-language original remains unchanged.

The corrected portions are underlined.

1. Details of the corrections

Page 1 of the English disclosure released on July 10, 2026

"1. Consolidated financial results for the fiscal year ended May 31, 2026"

(1) Consolidated operating results

Before correction

(Millions of yen)

	Net sales	Operating profit	Ordinary profit	Profit attributable to owners of parent
Fiscal year ended May 31, 2026	50,650	3,637	**3,810**	3,161

After correction

(Millions of yen)

	Net sales	Operating profit	Ordinary profit	Profit attributable to owners of parent
Fiscal year ended May 31, 2026	50,650	3,637	**3,812**	3,161

(2) EBITDA

Before correction

Fiscal year ended May 31, 2026: 8,024 million yen

Fiscal year ended May 31, **2026**: 6,952 million yen

After correction

Fiscal year ended May 31, 2026: 8,024 million yen

Fiscal year ended May 31, **2025**: 6,952 million yen

2. Reason for corrections

The corrections were made because certain information in the English translation was inconsistent with the Japanese-language original due to errors in the preparation of the English disclosure. The Japanese-language original remains unchanged.

End